MONTPELLIER, FRANCE — Sensorion announced that it has selected SENS-601, its gene therapy candidate for GJB2-related hearing loss, as the company’s lead gene therapy program after achieving several key regulatory milestones. The company has filed Clinical Trial Applications in Canada and France, with additional submissions planned in the United States and Australia by the end of 2026....
No actionable change — this is an early-stage regulatory milestone for a gene therapy still years from clinical availability.
GJB2 mutations are the most common cause of inherited hearing loss, so a gene therapy entering clinical-trial stages represents a meaningful step toward a potential biological treatment option.
- 01Sensorion selected SENS-601 as lead candidate for GJB2-related (genetic) hearing loss gene therapy.
- 02Clinical Trial Applications (CTAs) have been filed with regulators, marking a key pipeline milestone.
- 03GJB2 mutations are among the most frequent genetic causes of congenital hearing loss worldwide.
- 04The therapy is still pre-clinical-trial; no human efficacy or safety data have been published.
- 05This is a company press release without independent peer-reviewed evidence.
SENS-601 has been selected as Sensorion's lead gene therapy candidate for GJB2-related hearing loss.
press releaseunclearSensorion has filed Clinical Trial Applications and achieved key regulatory milestones for SENS-601.
press releasesupported